Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Eckstein

Showing results (151-160 of 263) with videos related to

Pageof 27
Sort By:
Journal for Immunotherapy of Cancer|February 17, 2021
Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitorsJian-Guo Zhou, Anna-Jasmina Donaubauer, Benjamin Frey, et al.
Genes|February 10, 2021
<i>TERT</i> Promoter Mutation Analysis of Whole-Organ Mapping Bladder CancersVeronika Weyerer, Markus Eckstein, Pamela L Strissel, et al.
BMC Cancer|November 19, 2021
Relevance of the time interval between surgery and adjuvant radio (chemo) therapy in HPV-negative and advanced head and neck carcinoma of unknown primary (CUP)Matthias Balk, Robin Rupp, Konstantin Mantsopoulos, et al.
BMC Cancer|March 20, 2020
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiationRonja Morsch, Michael Rose, Angela Maurer, et al.
European Urology|March 30, 2022
Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin ImmunotherapyRoman Mayr, Markus Eckstein, Ralph M Wirtz, et al.
Cancer Research|January 21, 2021
Bladder Tumor Subtype Commitment Occurs in Carcinoma <i>In Situ</i> Driven by Key Signaling Pathways Including ECM RemodelingAdrian Wullweber, Reiner Strick, Fabienne Lange, et al.
Frontiers in Immunology|November 17, 2022
Case report: Patient specific combination of surgery and immunotherapy in advanced squamous cell carcinoma of the head and neck - a case series and review of literatureManuel Olmos, Rainer Lutz, Tjark-Ole Büntemeyer, et al.
Elife|May 1, 2020
Collective forces of tumor spheroids in three-dimensional biopolymer networksChristoph Mark, Thomas J Grundy, Pamela L Strissel, et al.
Journal of Personalized Medicine|June 2, 2021
KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder CancerHendrik Jütte, Moritz Reike, Ralph M Wirtz, et al.
Frontiers in Oncology|May 10, 2021
Endogenous Retroviral-K Envelope Is a Novel Tumor Antigen and Prognostic Indicator of Renal Cell CarcinomaVeronika Weyerer, Pamela L Strissel, Christine Stöhr, et al.
Pageof 27

Showing results (151-160 of 263) with videos related to

Sort By:
Pageof 27
Journal for Immunotherapy of Cancer|February 17, 2021
Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitorsJian-Guo Zhou, Anna-Jasmina Donaubauer, Benjamin Frey, et al.
Genes|February 10, 2021
<i>TERT</i> Promoter Mutation Analysis of Whole-Organ Mapping Bladder CancersVeronika Weyerer, Markus Eckstein, Pamela L Strissel, et al.
BMC Cancer|November 19, 2021
Relevance of the time interval between surgery and adjuvant radio (chemo) therapy in HPV-negative and advanced head and neck carcinoma of unknown primary (CUP)Matthias Balk, Robin Rupp, Konstantin Mantsopoulos, et al.
BMC Cancer|March 20, 2020
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiationRonja Morsch, Michael Rose, Angela Maurer, et al.
European Urology|March 30, 2022
Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin ImmunotherapyRoman Mayr, Markus Eckstein, Ralph M Wirtz, et al.
Cancer Research|January 21, 2021
Bladder Tumor Subtype Commitment Occurs in Carcinoma <i>In Situ</i> Driven by Key Signaling Pathways Including ECM RemodelingAdrian Wullweber, Reiner Strick, Fabienne Lange, et al.
Frontiers in Immunology|November 17, 2022
Case report: Patient specific combination of surgery and immunotherapy in advanced squamous cell carcinoma of the head and neck - a case series and review of literatureManuel Olmos, Rainer Lutz, Tjark-Ole Büntemeyer, et al.
Elife|May 1, 2020
Collective forces of tumor spheroids in three-dimensional biopolymer networksChristoph Mark, Thomas J Grundy, Pamela L Strissel, et al.
Journal of Personalized Medicine|June 2, 2021
KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder CancerHendrik Jütte, Moritz Reike, Ralph M Wirtz, et al.
Frontiers in Oncology|May 10, 2021
Endogenous Retroviral-K Envelope Is a Novel Tumor Antigen and Prognostic Indicator of Renal Cell CarcinomaVeronika Weyerer, Pamela L Strissel, Christine Stöhr, et al.
Pageof 27